Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults

Phase 1 Completed 69 enrolled Melinta Therapeutics, Inc. Innovative Medicines Initiative · collab Universitätsklinikum Köln · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

This was a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study of the safety, tolerability, and pharmacokinetics of Minocin (minocycline) for injection in healthy adult participants.

Timeline

Start: 2017-04-20
Primary completion: 2018-02-08
Completion: 2018-02-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Minocycline	Small molecule	100 mg	Intravenous
Subject	Minocycline	Small molecule	200 mg	Intravenous
Subject	Minocycline	Small molecule	300 mg	Intravenous
Subject	Minocycline	Small molecule	400 mg	Intravenous
Subject	Minocycline	Small molecule	500 mg	Intravenous
Subject	Minocycline	Small molecule	600 mg	Intravenous

Indications

No indication recorded.